STOCK TITAN

Ionis Pharmaceuticals reported $943.7M in revenue and a $381.4M net loss for fiscal 2025. See the full IONS financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Ionis to present at upcoming investor conferences

Ionis plans webcast fireside chats at Wells Fargo and Morgan Stanley healthcare investor conferences in September 2026.

(Neutral)
(Neutral)
Tags
conferences
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

  • 21st Annual Wells Fargo Healthcare Conference on Thursday, September 10, 2026
  • Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026

A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – ir@ionis.com760-603-2331

Ionis Pharmaceuticals Media Contact:
Hayley Soffer – media@ionis.com – 760-603-4679

Source: Ionis Pharmaceuticals, Inc.